B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report) today and set a price target of $4.00. The company’s shares opened today at $1.50.
Mamtani covers the Healthcare sector, focusing on stocks such as Novavax, Altimmune, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -22.6% and a 25.21% success rate on recommended stocks.
Spectrum Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $6.67, which is a 344.67% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.
See the top stocks recommended by analysts >>
SPPI market cap is currently $243.7M and has a P/E ratio of -1.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.
Read More on SPPI:
- BofA Sees iPhone Pre-Order Numbers as Major Positive for (NASDAQ:AAPL)
- Brookline Capital Markets Keeps Their Buy Rating on Moderna (MRNA)
- Grasping Bitcoin’s Growing Dominance in Emerging Economies: Interview with AAX’s Ben Caselin
- UPDATE – Expanded Partnership Between Arteris and Arm to Accelerate Automotive Electronics
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
